Category: Bylvay

  • Cabotegravir (Apretude) for HIV-1 Pre-Exposure Prophylaxis

    Date:  February 21, 2022 Issue #:  1644 Summary:  The FDA has approved Apretude (ViiV Healthcare), an IM extended-release (ER) formulation of the integrase strand transfer inhibitor (INSTI) cabotegravir, for use every 2 months to prevent sexually acquired HIV-1 infection in at-risk adolescents and adults. Apretude is the first ER formulation to be FDA-approved for pre-exposure […]